Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients

NCT02070471 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

ST-segment Elevation Myocardial Infarction

Interventions

DRUG: Placebo
DRUG: LC28-0126 Dose A
DRUG: LC28-0126 Dose B
DRUG: LC28-0126 Dose C

Sponsor

LG Life Sciences